---
title: 'Antibody drug conjugates for glioblastoma: current progress toward clinical
  use'
date: '2023-11-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37955063/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231113170848&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'INTRODUCTION: Antibody drug conjugates (ADCs) are now a proven therapeutic
  class for many cancers, combining highly specific targeting with the potency of
  high effective payloads. This review summarizes the experience with ADCs in brain
  tumors and examines future paths for their use in these ...'
disable_comments: true
---
INTRODUCTION: Antibody drug conjugates (ADCs) are now a proven therapeutic class for many cancers, combining highly specific targeting with the potency of high effective payloads. This review summarizes the experience with ADCs in brain tumors and examines future paths for their use in these ...